Diego Adrianzen-Herrera, MD, MS
@diegoah66.bsky.social
Associate Professor of Medicine @UVMLarnerMed | Hematologist-Oncologist @UVMMedCenter | #BloodCancer #OutcomesResearch | Peruvian 🇵🇪
https://uvmcommunity.uvm.edu/portal/uvmcc_members?cmd=memberbio&netid=dadrianz
https://uvmcommunity.uvm.edu/portal/uvmcc_members?cmd=memberbio&netid=dadrianz
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations - Blood Cancer Journal
Blood Cancer Journal - Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations
www.nature.com
May 27, 2025 at 9:26 PM
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted
Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term
survival of 75 to 80%.
www.nejm.org
May 18, 2025 at 1:33 AM
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers
www.nature.com/articles/s41...
www.nature.com/articles/s41...
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms - Leukemia
Leukemia - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
www.nature.com
May 18, 2025 at 1:32 AM
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin | Blood Advances | American Society of Hematology
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Key PointsFLT3-ITD MRD identifies patients at high relapse risk after intensive chemotherapy with midostaurin.Conversion from FLT3-ITD MRDneg to FLT3-ITD M
ashpublications.org
December 18, 2024 at 12:49 AM
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin | Blood Advances | American Society of Hematology
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Reposted by Diego Adrianzen-Herrera, MD, MS
How insurance companies degrade the patient-doctor relationship, by Helen Ouyang, my friend and exceptional physician-author
gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com
gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com
December 12, 2024 at 2:54 PM
How insurance companies degrade the patient-doctor relationship, by Helen Ouyang, my friend and exceptional physician-author
gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com
gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com
Reposted by Diego Adrianzen-Herrera, MD, MS
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
December 6, 2024 at 7:58 PM
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
December 2, 2024 at 5:36 PM
Reposted by Diego Adrianzen-Herrera, MD, MS
8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier.
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
November 29, 2024 at 7:46 PM
8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier.
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed
#Hemesky
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
ashpublications.org
November 27, 2024 at 2:18 AM
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
ashpublications.org/blood/articl...
ashpublications.org/blood/articl...
Venetoclax + HMA for previously untreated Higher-Risk Myelodysplastic Syndromes and genotype signatures
onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com/doi/full/10....
Venetoclax and Hypomethylating Agent in Previously Untreated Higher‐Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real‐World Study
Click on the article title to read more.
onlinelibrary.wiley.com
November 23, 2024 at 9:06 PM
Venetoclax + HMA for previously untreated Higher-Risk Myelodysplastic Syndromes and genotype signatures
onlinelibrary.wiley.com/doi/full/10....
onlinelibrary.wiley.com/doi/full/10....
👇👇👇
Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine
ashpublications.org/blood/articl...
Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine
ashpublications.org/blood/articl...
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
ashpublications.org
November 22, 2024 at 8:45 PM
👇👇👇
Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine
ashpublications.org/blood/articl...
Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine
ashpublications.org/blood/articl...
Reposted by Diego Adrianzen-Herrera, MD, MS
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
www.fda.gov
November 17, 2024 at 2:23 PM
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
Very interesting 👇👇
Previous studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at Nature Genetics.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia - Nature Genetics
Analysis of exomes and transcriptomes from 100 African American patients with acute myeloid leukemia identifies ancestry-related variation in mutation profiles and survival. Refined risk classificatio...
www.nature.com
November 19, 2024 at 1:10 PM
Very interesting 👇👇
Reposted by Diego Adrianzen-Herrera, MD, MS
Not many papers change the way I think about AML, but this exceptional work shows how cell states and genetics intertwine to mediate venetoclax resistance, unifying previous studies by identifying RAS-mutated LSCs that are primed to produce myeloid cells #hemesky 🩸🧪 www.nature.com/articles/s41...
November 16, 2024 at 12:19 AM
Not many papers change the way I think about AML, but this exceptional work shows how cell states and genetics intertwine to mediate venetoclax resistance, unifying previous studies by identifying RAS-mutated LSCs that are primed to produce myeloid cells #hemesky 🩸🧪 www.nature.com/articles/s41...
New to Bluesky 🦋 Hello to all!
November 17, 2024 at 8:52 PM
New to Bluesky 🦋 Hello to all!